サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298243

血漿タンパク質治療市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2022-2031年

Plasma Protein Therapeutics Market By Product type, By Application, By End user : Global Opportunity Analysis and Industry Forecast, 2022-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 262 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血漿タンパク質治療市場：製品タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2022-2031年
出版日: 2023年03月01日
発行: Allied Market Research
ページ情報: 英文 262 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

血漿タンパク質治療の世界市場は、2021年には265億米ドルと評価され、2022年から2031年にかけてCAGR 5.2%で成長し、2031年には443億米ドルに達すると予測されています。

血漿タンパク質治療は、ヒト血漿から作られるバイオ医薬品のサブカテゴリーであり、様々な疾患の治療に使用されます。血漿タンパク質と呼ばれる天然成分は血液中に存在し、健康を維持し病気を予防するために不可欠です。免疫グロブリン、凝固因子、アルブミン、その他の特殊な血漿タンパク質など、様々な化合物が血漿タンパク質療法のカテゴリーに含まれます。これらの医薬品は、川崎病、免疫不全、血液疾患、肝臓疾患、自己免疫疾患、慢性多発性神経炎などの神経疾患など、さまざまな疾患の治療に使用されています。

血漿タンパク質治療市場は、アンメットニーズのある慢性疾患の有病率の増加、高齢化人口の増加、蛋白質治療技術の進歩、血漿蛋白質分野における研究開発の活発化などの要因によって牽引されています。特に発展途上国における慢性免疫疾患の罹患率の増加により、これらの製品に対する需要は今後も伸び続けると予想されます。さらに、新製品開拓と新製品承認は血漿タンパク質治療市場の成長促進要因として重要です。例えば、2020年2月にCSLベーリング社は、米国食品医薬品局（FDA）が全身性硬化症（SSc）治療における治験薬としてプリビジェンヌ（免疫グロブリン静注（ヒト）、10％液）をオーファンドラッグ指定したと発表しました。さらに、市場参入企業が戦略的提携を結び、大学や研究施設、その他の組織と協力することも市場成長の原動力となっています。さらに、企業は製品ポートフォリオを拡大し、市場での存在感を高め、新市場へのアクセスを獲得するために、中小企業を買収しています。このように、M&A、製品革新、流通網の拡大など、主要市場プレイヤーによる戦略の採用が増加していることが、血漿タンパク質治療市場の成長を促進しています。

Plasma Protein Therapeutics Market-IMG1

免疫疾患や自己免疫疾患など、さまざまな疾患に対して患者や医療関係者がより効果的で特異的な治療法を好むようになり、血漿タンパク質治療に対する需要が増加しています。血漿タンパク質治療は、従来の治療薬に比べ、有効性の向上、副作用の軽減、特定の疾患関連分子を標的とできるなど、さまざまな利点があります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • 先端治療薬に対する需要の高まり
      • 戦略採用の増加主要市場プレーヤー別
      • 製品承認と製品開発の増加
    • 阻害要因
      • 血漿タンパク質製品の取り扱いに関する厳しい規制
    • 機会
      • 技術の進歩
  • COVID-19、市場への影響分析

第4章 血漿タンパク質治療市場：製品タイプ別

  • 概要
    • 市場規模および予測
  • 免疫グロブリン
    • 主要市場動向、成長要因、成長機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • アルブミン
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 血漿由来第VIII因子
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 血漿タンパク質治療市場：用途別

  • 概要
    • 市場規模および予測
  • 血友病
    • 主要市場動向、成長要因、成長機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 特発性血小板減少性紫斑病
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 原発性免疫不全症
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 血漿タンパク質治療市場：エンドユーザー別

  • 概要
    • 市場規模および予測
  • 病院
    • 主な市場動向、成長要因、成長機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 血漿タンパク質治療市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：製品タイプ別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、成長機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：製品タイプ別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、成長機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：製品タイプ別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、成長機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 中国
      • 主要市場動向、成長要因、成長機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • オーストラリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 韓国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：製品タイプ別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ブラジル
      • 主要市場動向、成長要因、成長機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • サウジアラビア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 南アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他の地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品タイプ別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング（2021年）

第9章 企業プロファイル

  • Octapharma AG
  • Grifols, S.A.
  • Baxter International Inc.
  • ADMA Biologics Inc
  • Bio Products Laboratory Ltd
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Kedrion, SpA
  • Taibang Biological Group Co., Ltd
  • Bayer AG
図表

LIST OF TABLES

  • TABLE 01. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 02. PLASMA PROTEIN THERAPEUTICS MARKET FOR IMMUNOGLOBULIN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. PLASMA PROTEIN THERAPEUTICS MARKET FOR ALBUMIN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. PLASMA PROTEIN THERAPEUTICS MARKET FOR PLASMA DERIVED FACTOR VIII, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 07. PLASMA PROTEIN THERAPEUTICS MARKET FOR HEMOPHILIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. PLASMA PROTEIN THERAPEUTICS MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. PLASMA PROTEIN THERAPEUTICS MARKET FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 12. PLASMA PROTEIN THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. PLASMA PROTEIN THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 20. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 21. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 24. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 38. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 39. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 40. UK PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 41. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 42. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 43. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 57. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 58. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 59. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 60. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 61. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 62. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 88. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 89. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 90. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 91. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 92. OCTAPHARMA AG: KEY STRATERGIES
  • TABLE 93. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 94. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 95. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 96. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 97. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 98. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 99. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 100. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
  • TABLE 101. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 102. ADMA BIOLOGICS INC: KEY EXECUTIVES
  • TABLE 103. ADMA BIOLOGICS INC: COMPANY SNAPSHOT
  • TABLE 104. ADMA BIOLOGICS INC: PRODUCT SEGMENTS
  • TABLE 105. ADMA BIOLOGICS INC: PRODUCT PORTFOLIO
  • TABLE 106. ADMA BIOLOGICS INC: KEY STRATERGIES
  • TABLE 107. BIO PRODUCTS LABORATORY LTD: KEY EXECUTIVES
  • TABLE 108. BIO PRODUCTS LABORATORY LTD: COMPANY SNAPSHOT
  • TABLE 109. BIO PRODUCTS LABORATORY LTD: PRODUCT SEGMENTS
  • TABLE 110. BIO PRODUCTS LABORATORY LTD: PRODUCT PORTFOLIO
  • TABLE 111. BIO PRODUCTS LABORATORY LTD: KEY STRATERGIES
  • TABLE 112. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 113. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 114. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 117. CSL LIMITED: KEY EXECUTIVES
  • TABLE 118. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 119. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 120. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 121. CSL LIMITED: KEY STRATERGIES
  • TABLE 122. KEDRION, SPA: KEY EXECUTIVES
  • TABLE 123. KEDRION, SPA: COMPANY SNAPSHOT
  • TABLE 124. KEDRION, SPA: PRODUCT SEGMENTS
  • TABLE 125. KEDRION, SPA: PRODUCT PORTFOLIO
  • TABLE 126. KEDRION, SPA: KEY STRATERGIES
  • TABLE 127. TAIBANG BIOLOGICAL GROUP CO., LTD: KEY EXECUTIVES
  • TABLE 128. TAIBANG BIOLOGICAL GROUP CO., LTD: COMPANY SNAPSHOT
  • TABLE 129. TAIBANG BIOLOGICAL GROUP CO., LTD: PRODUCT SEGMENTS
  • TABLE 130. TAIBANG BIOLOGICAL GROUP CO., LTD: PRODUCT PORTFOLIO
  • TABLE 131. BAYER AG: KEY EXECUTIVES
  • TABLE 132. BAYER AG: COMPANY SNAPSHOT
  • TABLE 133. BAYER AG: PRODUCT SEGMENTS
  • TABLE 134. BAYER AG: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN PLASMA PROTEIN THERAPEUTICS MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPLASMA PROTEIN THERAPEUTICS MARKET
  • FIGURE 10. PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR IMMUNOGLOBULIN, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR ALBUMIN, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR PLASMA DERIVED FACTOR VIII, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR HEMOPHILIA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR PRIMARY IMMUNODEFICIENCY DISORDER, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PLASMA PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 23. PLASMA PROTEIN THERAPEUTICS MARKET BY REGION, 2021
  • FIGURE 24. U.S. PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA PLASMA PROTEIN THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: PLASMA PROTEIN THERAPEUTICS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. ADMA BIOLOGICS INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. ADMA BIOLOGICS INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. ADMA BIOLOGICS INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A12692

The global plasma protein therapeutics market was valued at $26.5 billion in 2021, and is projected to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

Plasma protein therapeutics are a subcategory of biopharmaceuticals made from human blood plasma and are used to treat a range of diseases. Natural components called plasma proteins are present in blood and are essential for preserving good health and preventing disease. Various compounds, such as immunoglobulin, clotting factors, albumin, and other specialized plasma proteins, are included in the category of plasma protein therapies. These medicines are used to treat a range of illnesses, such as Kawasaki disease, immunological deficiencies, blood problems, liver ailments, autoimmune diseases, and neurological disorders such as chronic polyneuropathy.

The market for plasma protein therapeutics is driven by factors such as an increase in the prevalence of chronic diseases with unmet needs, rise in an aging population, and advancements in protein therapies technology and rise in R&D in the plasma protein field. The demand for these products is expected to continue to grow due to an increase in the incidence of chronic immunological diseases, particularly in developing countries. In addition, new product development and new product approval are significant drivers of growth for the plasma protein therapeutics market. For an instance, in February 2020 CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted Privigenne (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc). Moreover, market growth is also driven by market participants forming strategic alliances and working together with universities, research facilities, and other organizations. Furthermore, companies are acquiring smaller players to expand their product portfolio, increase their market presence, and gain access to new markets. Thus, the rise in adoption of strategies by key market players, such as mergers and acquisitions, product innovation, and expanding distribution networks, is driving the growth of the plasma protein therapeutics market.

Plasma Protein Therapeutics Market - IMG1

There is an increase in the demand for plasma protein therapeutics as patients and medical professionals prefer more effective and specific treatments for a variety of diseases, including immunological disorders and autoimmune disorders. They offer a variety of advantages over traditional treatment, including improved efficacy, fewer side effects, and the ability to target specific disease-related molecules.

In addition, plasma protein therapeutics have been gaining significant attention in recent years due to their potential to treat a wide range of medical conditions, including immune disorders, and bleeding disorders. Rise in demand for advanced therapeutics, as patients and healthcare professionals look for more effective and focused therapies for various diseases also drives the market growth.

However, stringent guidelines for storage, testing, and collection from donors, of plasma is expected to restrain the growth of the plasma protein therapeutics market. On the other hand, development of targeted plasma protein therapies that can be used to treat specific disorders has been made possible by modifications in analytical and diagnostic technologies. Research and technological advancements have made it possible to create novel plasma protein therapies that improve patient outcomes. Thus, technological advancements in the field of plasma protein therapeutics offer a significant opportunity for market growth.

The plasma protein therapeutics market is segmented into product type, application, end user and region. By product type, the market is categorized into immunoglobulin, albumin, plasma factor derived VIII, and others. By application, the market is segregated into hemophilia, idiopathic thrombocytopenic purpura , primary immunodeficiency, and others. By end user, the market is categorized into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global plasma protein therapeutics market are: ADMA Biologics Inc, Bayer AG, Bio products laboratory, Baxter International, CSL Limited, Grifsols, Kedrion SpA, Octapharma USA Inc, Taibang Biological Group Co. Ltd, and Takeda Pharmaceutical Company Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the plasma protein therapeutics market analysis from 2021 to 2031 to identify the prevailing plasma protein therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the plasma protein therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global plasma protein therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product type

  • Immunoglobulin
  • Albumin
  • Plasma derived factor VIII
  • Others

By Application

  • Hemophilia
  • Idiopathic thrombocytopenic purpura
  • Primary immunodeficiency disorder
  • Others

By End user

  • Hospitals
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Bayer AG
  • Bio Products Laboratory Ltd
  • Takeda Pharmaceutical Company Limited
  • Grifols, S.A.
  • Baxter International Inc.
  • Kedrion, SpA
  • Octapharma AG
  • CSL Limited
  • ADMA Biologics Inc
  • Taibang Biological Group Co., Ltd

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in demand for advanced therapeutics
      • 3.4.1.2. Rise in adoption of strategies by key market players
      • 3.4.1.3. Increase in product approval and product development
    • 3.4.2. Restraints
      • 3.4.2.1. Strict regulation for handling plasma protein products
    • 3.4.3. Opportunities
      • 3.4.3.1. Technological advancements
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunoglobulin
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Albumin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Plasma derived factor VIII
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hemophilia
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Idiopathic thrombocytopenic purpura
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Primary immunodeficiency disorder
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Others
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: PLASMA PROTEIN THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Product type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End user
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Product type
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.1.4. Market size and forecast, by End user
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Product type
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.2.4. Market size and forecast, by End user
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Product type
      • 7.2.5.3.3. Market size and forecast, by Application
      • 7.2.5.3.4. Market size and forecast, by End user
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Product type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End user
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Product type
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.1.4. Market size and forecast, by End user
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Product type
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.2.4. Market size and forecast, by End user
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Product type
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.3.4. Market size and forecast, by End user
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Product type
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.4.4. Market size and forecast, by End user
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Product type
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.5.4. Market size and forecast, by End user
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Product type
      • 7.3.5.6.3. Market size and forecast, by Application
      • 7.3.5.6.4. Market size and forecast, by End user
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Product type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End user
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Product type
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.1.4. Market size and forecast, by End user
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Product type
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.2.4. Market size and forecast, by End user
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Product type
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.3.4. Market size and forecast, by End user
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Product type
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.4.4. Market size and forecast, by End user
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Product type
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.5.4. Market size and forecast, by End user
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Product type
      • 7.4.5.6.3. Market size and forecast, by Application
      • 7.4.5.6.4. Market size and forecast, by End user
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Product type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End user
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Product type
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.1.4. Market size and forecast, by End user
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Product type
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.2.4. Market size and forecast, by End user
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Product type
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.3.4. Market size and forecast, by End user
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Product type
      • 7.5.5.4.3. Market size and forecast, by Application
      • 7.5.5.4.4. Market size and forecast, by End user

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Octapharma AG
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Grifols, S.A.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Baxter International Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. ADMA Biologics Inc
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Bio Products Laboratory Ltd
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Takeda Pharmaceutical Company Limited
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. CSL Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Kedrion, SpA
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Taibang Biological Group Co., Ltd
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Bayer AG
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance